Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 8, November, p. 1257–1261

doi: 10.17219/acem/66076

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Distribution of polymorphisms rs12979860, rs8099917 and rs12980275 IL28B in patients with chronic hepatitis C

Joanna Wysocka-Leszczyńska1,A,B,C,D,E,F, Ewelina Kałużna2,B,C,D,E,F, Bogna Świątek-Kościelna2,B,C,D,E,F, Ewelina Gowin3,D,E,F, Jan Nowak2,E,F, Iwona Bereszyńska4,B, Iwona Mozer-Lisewska4,E,F, Jacek Wysocki1,E,F, Danuta Januszkiewicz-Lewandowska2,5,6,A,E,F

1 Department of Health Prevention, Poznan University of Medical Sciences, Poland

2 Department of Molecular Pathology, Institute of Human Genetics PASc, Poznań, Poland

3 Department of Family Medicine, Poznan University of Medical Sciences, Poland

4 Department and Clinic of Infectious Diseases, Poznan University of Medical Sciences, Poland

5 Clinic of Oncology, Hematology and Pediatric Transplantology, Poznan University of Medical Sciences, Poznań, Poland

6 Department of Medical Diagnostics, Poznań, Poland

Abstract

Background. The prognosis concerning the treatment of patients with chronic hepatitis C (CHC) is closely related to the genotype of the virus as well as to the factors dependent on the patient. It was proved that polymorphisms of the gene encoding interleukin 28B (IL28B) are associated with sustained viral response, which in the case of profitable variants of IL28B polymorphisms may reach up to 87% of the patients.
Objectives. The aim of the study is to determine the prevalence of alleles and distribution of IL28B polymorphisms genotypes in the examined group of patients with CHC in Wielkopolska Province.
Material and Methods. A total of 710 people with diagnosed hepatitis C virus were examined in order to determine the distribution of polymorphisms of gene IL28B rs12979860, rs8099917 and rs12980275. The polymorphisms were evaluated by sequencing of PCR products.
Results. The most often noted profitable variant was genotype TT for polymorphism rs8099917 present in 43.5% of the patients, next was AA rs12980275 in 22.5%. The rarest was the profitable variant CC of the polymorphism rs12979860 present in 17.5% of the patients. An occurrence of at least 2 IL28B polymorphisms in the preferred variants (homozygote CC, TT, AA) was found in 239 out of 710 (34%) patients, among which 117 patients had favorable genotypes for all 3 examined polymorphisms.
Conclusion. The SNP distribution of gene IL28 with fixed prognostic value in the population of patients with chronic hepatitis C is different from the general population, and shows the need to evaluate polymorphisms prior to treatment.

Key words

HCV, hepatitis C, treatment

References (15)

  1. Tyczyno M. HCV genotypes among patients diagnosed in Bydgoszcz. Med Sci Rev Hepatol. 2007;7:77–79.
  2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet. 2001;358:958–965.
  3. Domagalski K, Tretyn A, Pawłowska M, Szczepanek J, Halota W. Action of type III IFNs and their roles in immune responses. Postepy Hig Med Dosw. 2010;64:522–533.
  4. Kotenko S, Gallagher G, Baurin VV, et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nature Immunology. 2003;4:69–77.
  5. Ge D, Fellay J, Thompson Aj, et al. Genetic variation in IL28B predicts hepatitis C treatment–induced viral clearance. Nature. 2009;461:399–401.
  6. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.
  7. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin 28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120–129.
  8. Aparicio E, Parera M, Franco S, et al. IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One. 2010;29:e13771. doi: 10.1371/journal.pone.0013771.
  9. Knapp S, Warshow U, Ho KMA, et al. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology. 2011;141:320–325.
  10. Domagalski K, Pawłowska M, Tretyn A, et al. Association of IL28B with the response to peginterferon plus ribavirin combined in Polish patients infected with HCV genotype 1 and 4. Hepat Mon. 2013;13:e13678. doi: 10.5812/hepatmon.13678.
  11. Kozłowski P, Pogorzelska J, Łapiński TW, et al. The occurrence of HCV genotypes and single polynucleotide polymorphisms of rs12979860 among HCV infected patients in northeastern Poland. Przegl Epidemiol. 2012;66:25–31.
  12. Kaczor MP, Seczyńska M, Szczeklik W, Sanak M. IL28B polymorphism (rs12979860) associated with clearance of HCV infection in Poland: Systematic review of its prevalence in chronic hepatitis C patients and general population frequency. Pharmacological Reports. 2015;67:260–266.
  13. Fabris C, Falleti E, Cussigh A, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: Role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011;54:716–722.
  14. Lutz P, Wasmuth JC, Nischalke HD, et al. Progression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rs12979860 polymorphism of the IL28B gene. Eur J Med Res. 2011;16:335–341.
  15. Par A, Par G, Tornai I, et al. IL28B and IL10R −1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort. BMC Research Notes. 2014;7:12.